Gina Wallar joined Flagship in March 2023 as Chief Commercial Officer. Gina brings over 20 years’ experience in the pharma services and diagnostics industry leading global sales teams, managing people, and spearheading business development to support sustainable growth.

Prior to joining Flagship Biosciences, Dr. Wallar acted as Senior Vice President for Fulgent Genetics where she led their sales and business development efforts. Prior to that, Dr. Wallar held numerous positions at Neogenomics Laboratories from 2014-2022, most recently having acted as their President of Pharma Services. She also held leadership roles in the Clinical Division and as Director of Scientific Affairs and Project Management. For 12 years (from 2002-2014), Dr. Wallar served as the Director for LabCorp Clinical Trials in Los Angeles, CA and oversaw hundreds of programs supporting drug development, including the first approvals for PD-L1 testing.

Dr. Wallar earned her PhD at UCLA in Molecular Epidemiology, studying risk susceptibility polymorphisms in the cancer stem cell pathway. She has an MPH from Boston University in Epidemiology and Biostatistics. Past research interests have included risk factors for identifying susceptibility to cancer as well as molecular prognostic indicators of disease.